Dutertre Sébastien, Ulens Chris, Büttner Regina, Fish Alexander, van Elk René, Kendel Yvonne, Hopping Gene, Alewood Paul F, Schroeder Christina, Nicke Annette, Smit August B, Sixma Titia K, Lewis Richard J
Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
EMBO J. 2007 Aug 22;26(16):3858-67. doi: 10.1038/sj.emboj.7601785. Epub 2007 Jul 26.
Neuronal nAChRs are a diverse family of pentameric ion channels with wide distribution throughout cells of the nervous and immune systems. However, the role of specific subtypes in normal and pathological states remains poorly understood due to the lack of selective probes. Here, we used a binding assay based on acetylcholine-binding protein (AChBP), a homolog of the nicotinic acetylcholine ligand-binding domain, to discover a novel alpha-conotoxin (alpha-TxIA) in the venom of Conus textile. Alpha-TxIA bound with high affinity to AChBPs from different species and selectively targeted the alpha(3)beta(2) nAChR subtype. A co-crystal structure of Ac-AChBP with the enhanced potency analog TxIA(A10L), revealed a 20 degrees backbone tilt compared to other AChBP-conotoxin complexes. This reorientation was coordinated by a key salt bridge formed between Arg5 (TxIA) and Asp195 (Ac-AChBP). Mutagenesis studies, biochemical assays and electrophysiological recordings directly correlated the interactions observed in the co-crystal structure to binding affinity at AChBP and different nAChR subtypes. Together, these results establish a new pharmacophore for the design of novel subtype-selective ligands with therapeutic potential in nAChR-related diseases.
神经元烟碱型乙酰胆碱受体(nAChRs)是一个由五聚体离子通道组成的多样化家族,广泛分布于神经系统和免疫系统的细胞中。然而,由于缺乏选择性探针,特定亚型在正常和病理状态下的作用仍知之甚少。在此,我们基于乙酰胆碱结合蛋白(AChBP)(烟碱型乙酰胆碱配体结合域的同源物)进行结合测定,在织锦芋螺毒液中发现了一种新型α-芋螺毒素(α-TxIA)。α-TxIA与来自不同物种的AChBP具有高亲和力结合,并选择性靶向α(3)β(2) nAChR亚型。Ac-AChBP与增强效力类似物TxIA(A10L)的共晶体结构显示,与其他AChBP-芋螺毒素复合物相比,主链倾斜了20度。这种重新定向由Arg5(TxIA)和Asp195(Ac-AChBP)之间形成的关键盐桥协调。诱变研究、生化测定和电生理记录直接将共晶体结构中观察到的相互作用与AChBP和不同nAChR亚型的结合亲和力相关联。总之,这些结果为设计在nAChR相关疾病中具有治疗潜力的新型亚型选择性配体建立了一种新的药效基团。